載入中
CDT Equity Inc., a data-driven biopharmaceutical company, focuses on identifying, enhancing, and monetising therapeutic assets. The company’s pipeline includes AZD1656, a glucokinase activator that is in Phase II trials for the treatment of autoimmune disorders, including uveitis, Hashimoto’s thyroiditis, preterm labor, and renal transplant; AZD5658, which is in Phase I clinical trial for the treatment of Type 2 Diabetes Mellitus; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. It also provides treatments for inflammatory disorders, oncology, dermatology, rare diseases and animal health. The company was formerly known as Conduit Pharmaceuticals Inc. and changed its name to CDT Equity Inc. in August 2025. The company was founded in 2019 and is based in Naples, Florida.
前收盤價
US$0.718
−US$0.082 · -10.25%
盤中時間採用ET。市場資料可能有所延遲。
CDT Equity Inc., a data-driven biopharmaceutical company, focuses on identifying, enhancing, and monetising therapeutic assets. The company’s pipeline includes AZD1656, a glucokinase activator that is in Phase II trials for the treatment of autoimmune disorders, including uveitis, Hashimoto’s thyroiditis, preterm labor, and renal transplant; AZD5658, which is in Phase I clinical trial for the treatment of Type 2 Diabetes Mellitus; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. It also provides treatments for inflammatory disorders, oncology, dermatology, rare diseases and animal health. The company was formerly known as Conduit Pharmaceuticals Inc. and changed its name to CDT Equity Inc. in August 2025. The company was founded in 2019 and is based in Naples, Florida.
日內區間
目前US$0.718
52週區間
目前US$0.718
盤中時間採用ET。市場資料可能有所延遲。
GoAI 評分
賣出
估值
46
合理估值
情緒
55
多空交錯
風險
73
高風險
動能
17
強勢下行
完整 GoAI 研究
繼續查看更深入的依據、催化因素和風險。
CDT Equity Inc., a data-driven biopharmaceutical company, focuses on identifying, enhancing, and monetising therapeutic assets. The company’s pipeline includes AZD1656, a glucokinase activator that is in Phase II trials for the treatment of autoimmune disorders, including uveitis, Hashimoto’s thyroiditis, preterm labor, and renal transplant; AZD5658, which is in Phase I clinical trial for the treatment of Type 2 Diabetes Mellitus; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. It also provides treatments for inflammatory disorders, oncology, dermatology, rare diseases and animal health. The company was formerly known as Conduit Pharmaceuticals Inc. and changed its name to CDT Equity Inc. in August 2025. The company was founded in 2019 and is based in Naples, Florida.
日內區間
目前US$0.718
52週區間
目前US$0.718
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 研究與開發 | 505.4萬 USD | 337.8萬 USD | 9萬 USD | 11.1萬 USD | 28.3萬 USD |
| 銷售、一般及管理費用 | 3170.3萬 USD | 1204.1萬 USD | 517.2萬 USD | 304.9萬 USD | 289萬 USD |
| 營業費用 | 3675.7萬 USD | 1541.9萬 USD | 526.2萬 USD | 316萬 USD | 317.3萬 USD |
| 利息收入 | 2.8萬 USD | 1.3萬 USD | 1.5萬 USD | 197.6萬 USD | — |
| 利息支出 | 31.9萬 USD | 150.6萬 USD | 21.1萬 USD | — | — |
| 折舊和攤銷 | 242.5萬 USD | 45.7萬 USD | — | — | — |
| 營業利益 | −3675.7萬 USD | −1541.9萬 USD | −526.2萬 USD | −316萬 USD | −317.3萬 USD |
| 淨利 | −3922.4萬 USD | −1780.2萬 USD | −53.5萬 USD | −488.7萬 USD | −365.7萬 USD |
公司資料更新於 2026年10月11日。
近期已公布業績
近期已公布業績
| 行動 | 生效日期 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股票分割 | 2026年9月29日 | 1:25 | — | — |
股票分割 | 2026年7月20日 | 1:10 | — | — |
股票分割 | 2026年3月27日 | 1:25 | — | — |
股票分割 | 2025年10月13日 | 1:8 | — | — |
股票分割 | 2025年5月20日 | 1:15 | — | — |
股票分割 | 2025年1月27日 | 1:100 | — | — |
已生效 2026年9月29日
1:25
已生效 2026年7月20日
1:10
已生效 2026年3月27日
1:25
已生效 2025年10月13日
1:8
已生效 2025年5月20日
1:15
已生效 2025年1月27日
1:100
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
